Beta Bionics Announces First Quarter 2026 Financial Results
Beta Bionics, Inc. reported its financial results for the first quarter of 2026 and raised its full-year guidance. The company is recognized for developing advanced diabetes management solutions and will host a conference call to discuss its performance. The report includes a non-GAAP financial measure, adjusted EBITDA, which Beta Bionics believes is useful for evaluating operating performance despite certain limitations.
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026.